Skip to main content
Fig. 4 | BMC Medical Genomics

Fig. 4

From: Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer

Fig. 4

Association between BTNL9 expression and clinical features in patients with THCA based on TCGA datasets. BTNL9 expression levels were stratified by (A) tumor T stage, (B) tumor N stage, (C) extrathyroidal extension, (D) pathologic stage, (E) histological type, (F) primary neoplasm focus type, (G) residual tumor, (H) thyroid gland disorder history and (I) PFI event. TCGA, The Cancer Genome Atlas; THCA, thyroid carcinoma; PFI, progress-free interval. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page